Prevalence and Predictors of Metabolic Syndrome Among Patients Attending an Outpatient Clozapine Clinic in Australia

被引:39
作者
Brunero, Scott
Lamont, Scott
Fairbrother, Greg
机构
[1] Prince Wales Hosp, Mental Hlth Serv, Sydney, NSW, Australia
[2] Prince Wales Hosp, Nursing Educ & Res Unit, Sydney, NSW, Australia
关键词
ANTIPSYCHOTIC-DRUGS; PSYCHIATRIC-PATIENTS; WEIGHT-GAIN; SCHIZOPHRENIA; TRIAL; RISK; MEDICATIONS; INPATIENTS; DISORDERS; SYMPTOMS;
D O I
10.1016/j.apnu.2008.06.007
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Objective: This study aimed to determine the prevalence and predictors of metabolic syndrome in an outpatient clozapine clinic in Australia. Methods: Metabolic syndrome is a cluster of some of the most dangerous cardiovascular risk factors, and its high prevalence in people with mental illness has been demonstrated. Patients attending a clozapine clinic were screened for the following: age, gender, ethnicity, waist circumference, blood pressure, high-density lipoprotein level, low-density lipoprotein level, blood sugar levels, total cholesterol level, triglycerides level, weight, body mass index, insulin resistance level, length of time on clozapine, clozapine dose, smoking status, family history of diabetes and cardiovascular disease, and personal history of polycystic ovarian syndrome. All the variables that were found to be significantly associated with metabolic syndrome were entered into a multivariate logistic regression analysis. Results: Seventy-three patients were screened for metabolic syndrome using the International Diabetes Federation's (2007) definition. Forty-five (61.6%) patients met the criteria for the syndrome. Increased blood sugar level, high diastolic blood pressure, older age, increased waist circumference, raised triglycerides level, and higher body mass index emerged as significant predictors of metabolic syndrome in the sample. Conclusions: This study adds further support for the systematic screening for metabolic syndrome in patients receiving dozapine. The need for intervention programs which screen for and address the modifiable risk factors of metabolic syndrome is discussed. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:261 / 268
页数:8
相关论文
共 39 条
[1]  
Alphs LD, 1999, J CLIN PSYCHIAT, V60, P39
[2]  
BABIDGE N, 2001, ACTA PSYCHIAT SCAND, V103, P81
[3]   Monitoring the safe use of clozapine - A consensus view from Victoria, Australia [J].
Berk, Michael ;
Fitzsimons, Joanna ;
Lambert, Timothy ;
Pantelis, Christos ;
Kulkarni, Jayashri ;
Castle, David ;
Ryan, Elizabeth W. ;
Jespersen, Sean ;
McGorry, Pat ;
Berger, Gregor ;
Kuluris, Bill ;
Callaly, Tom ;
Dodd, Seetal .
CNS DRUGS, 2007, 21 (02) :117-127
[4]   The Blue Card: a hand-held health record card for mental health consumers with comorbid physical health risk [J].
Brunero, Scott ;
Lamont, Scott ;
Myrtle, Lucy ;
Fairbrother, Greg .
AUSTRALASIAN PSYCHIATRY, 2008, 16 (04) :238-243
[5]  
Colton Craig W, 2006, Prev Chronic Dis, V3, pA42
[6]   Does antipsychotic polypharmacy increase the risk for metabolic syndrome? [J].
Correll, Christoph U. ;
Frederickson, Anne M. ;
Kane, John M. ;
Manu, Peter .
SCHIZOPHRENIA RESEARCH, 2007, 89 (1-3) :91-100
[7]  
*DEP HLTH AG, 1999, NAT SUIC PREV STRAT
[8]   Prevalence and correlates of diabetes in national schizophrenia samples [J].
Dixon, L ;
Weiden, P ;
Delahanty, J ;
Goldberg, R ;
Postrado, L ;
Lucksted, A ;
Lehman, A .
SCHIZOPHRENIA BULLETIN, 2000, 26 (04) :903-912
[9]   Long-term treatment with atypical antipsychotics and the risk of weight gain - A literature analysis [J].
Gentile, S .
DRUG SAFETY, 2006, 29 (04) :303-319
[10]   Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: A retrospective chart review [J].
Goethe, John W. ;
Szarek, Bonnie L. ;
Caley, Charles F. ;
Woolley, Stephen B. .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (01) :22-28